Publications: OV16 secondary analysis and MA17/MA17R meta analysis

CA-125 (cancer antigen 125) is a cell surface protein that can be measured in the blood. Levels of CA-125 are often increased in ovarian cancers that express this protein. Previous studies suggested that a single measurement or a summary of a limited number of measurements of the levels of CA125 may be used to forecast the results of treatments for patients with ovarian cancer. In this study, we found that the patterns of change in the levels of CA125 within three or six months after the start of chemotherapy provide more direct information on the results of chemotherapy treatment. Specifically, our study demonstrated a decreased risk of progression and death for patients whose CA125 levels were low at the start of the treatment and remained low during the treatment and an increased risk when patients’ CA125 levels remained elevated. This information may be useful for patient monitoring.

 

Yin C, Ethier J-L, Carey MS, Tu D, Zheng X. Trajectories of Cancer Antigen 125 (CA125) Within 3 and 6 Months After the Initiation of Chemotherapy Treatment for Advanced Ovarian Cancer and Clinical Outcomes: A Secondary Analysis of Data from a Phase III Clinical Trial. Current Oncology 32: 390. 2025. https://www.mdpi.com/1718-7729/32/7/390 

 

 

In postmenopausal women with oestrogen receptor-positive early breast cancer, 5 years of adjuvant tamoxifen substantially reduces 15-year recurrence and mortality; aromatase inhibitor treatment (AIT) is even more effective. Researchers assess the effects of further AIT among women recurrence-free after at least 5 years of endocrine therapy.

 

Early Breast Cancer Trialists Collaborative Group (EBCTCG). Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22,031 postmenopausal women already treated with at least 5 years of endocrine therapy. The Lancet 406: 603-614. 2025. https://doi.org/10.1016/S0140-6736(25)01013-X